Comparison of two high-doses of oral methylprednisolone for multiple sclerosis relapses: A pilot, multicenter, randomized, double-blind, non-inferiority trial.

08:00 EDT 23rd October 2018 | BioPortfolio

Summary of "Comparison of two high-doses of oral methylprednisolone for multiple sclerosis relapses: A pilot, multicenter, randomized, double-blind, non-inferiority trial."

Oral or intravenous methylprednisolone at ≥500mg/day/5 days is recommended for multiple sclerosis (MS) relapses. Nonetheless, the optimal dose remains uncertain. We compare clinical and radiological effectiveness, safety, and quality-of-life (QoL) of oral methylprednisolone (oMP) 1250mg/day (standard high-dose) vs 625mg/day (lesser high-dose), both for 3 days, in MS relapses.


Journal Details

This article was published in the following journal.

Name: European journal of neurology
ISSN: 1468-1331


DeepDyve research library

PubMed Articles [25623 Associated PubMed Articles listed on BioPortfolio]

Toxic liver injury after high-dose methylprednisolone in people with multiple sclerosis.

The standard therapy of multiple sclerosis (MS) relapse is high-dose pulse corticosteroid therapy. Although commonly applied and usually well tolerated it may as well carry certain risks for people wi...

Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews.

In patients with relapsing forms of multiple sclerosis (MS), relapses are often unrecognized. These missed relapses have broad implications for the conduct of clinical trials as well as for the care a...

Azathioprine-induced pellagra in neuromyelitis optica: A case report and review of literature.

Neuromyelitis optica (NMO), also known as Devic's disease, is a classical autoimmune disorder of the central nervous system (CNS). The relapsing-remitting disease course contributes to application of ...

Use of the new oral disease-modifying therapies for multiple sclerosis in British Columbia, Canada: the first five-years.

Little is known about the use of the new oral disease-modifying therapies (DMTs: fingolimod, dimethyl fumarate, teriflunomide) for multiple sclerosis (MS) in clinical practice. We describe their rate ...

Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.

To examine persistence and adherence to the oral disease-modifying therapies (DMTs) for multiple sclerosis (MS).

Clinical Trials [17023 Associated Clinical Trials listed on BioPortfolio]

Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks

This clinical trial compares the relative efficacy of treating acute exacerbations of relapsing forms of Multiple Sclerosis with equivalent doses of oral and intravenous (IV) methylprednis...

Imatinib for Multiple Sclerosis (MS) Relapses

To investigate if treatment with Imatinib results in a better outcome than standard care in form of Methylprednisolone(MP) after MS-associated relapses.

Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis

The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS)...

Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis

Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results,...

Efficacy and Safety of Fingolimod in Patients With Relapsing-Remitting Multiple Sclerosis With Optional Extension Phase

This study will assess safety, tolerability and efficacy of two doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting mu...

Medical and Biotech [MESH] Definitions

A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)

A water-soluble ester of METHYLPREDNISOLONE used for cardiac, allergic, and hypoxic emergencies.

A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS.

An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

Comparison of various psychological, sociological, or cultural factors in order to assess the similarities or diversities occurring in two or more different cultures or societies.

Quick Search


DeepDyve research library

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...

Searches Linking to this Article